Effects of a novel M4 muscarinic positive allosteric modulator on behavior and cognitive deficits relevant to Alzheimer's disease and schizophrenia in rhesus monkey

Evaluation of the efficacy of pimavanserin in the treatment of agitation and aggression in patients with Alzheimer's disease psychosis: a post hoc analysis

(2020) Clive G. Ballard et al.   INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY

Psychosis in Alzheimer’s Disease

(2020) Clive Ballard et al.   Current Neurology and Neuroscience Reports

Discovery, Optimization, and Biological Characterization of 2,3,6‐Trisubstituted Pyridine‐Containing M 4 Positive Allosteric Modulators

(2019) Jeffrey W. Schubert et al.   ChemMedChem

Efficacy and Safety of Brexpiprazole for the Treatment of Agitation in Alzheimer's Dementia: Two 12-Week, Randomized, Double-Blind, Placebo-Controlled Trials

(2019) George T. Grossberg et al.   AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY

Cognitive enhancement and antipsychotic-like activity following repeated dosing with the selective M 4 PAM VU0467154

(2018) Robert W. Gould et al.   NEUROPHARMACOLOGY

Positive allosteric modulation of M 1 and M 4 muscarinic receptors as potential therapeutic treatments for schizophrenia

(2018) Samantha E. Yohn et al.   NEUROPHARMACOLOGY

Current status of muscarinic M1 and M4 receptors as drug targets for neurodegenerative diseases

(2018) Christian C. Felder et al.   NEUROPHARMACOLOGY

Muscarinic receptor subtype distribution in the central nervous system and relevance to aging and Alzheimer's disease

(2018) E.P. Lebois et al.   NEUROPHARMACOLOGY

Nicotinic alpha 7 receptor agonists EVP-6124 and BMS-933043, attenuate scopolamine-induced deficits in visuo-spatial paired associates learning

(2017) Michael R. Weed et al.   PLoS One

Antipsychotic-like Effects of M 4 Positive Allosteric Modulators Are Mediated by CB 2 Receptor-Dependent Inhibition of Dopamine Release

(2016) Daniel J. Foster et al.   NEURON

State-dependent alterations in sleep/wake architecture elicited by the M4 PAM VU0467154 – Relation to antipsychotic-like drug effects

(2016) Robert W. Gould et al.   NEUROPHARMACOLOGY

Behavioral and qEEG effects of the PDE10A inhibitor THPP-1 in a novel rhesus model of antipsychotic activity

(2016) Joshua D. Vardigan et al.   PSYCHOPHARMACOLOGY

The muscarinic system, cognition and schizophrenia

(2015) Sean P. Carruthers et al.   NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS

Selective Activation of M4 Muscarinic Acetylcholine Receptors Reverses MK-801-Induced Behavioral Impairments and Enhances Associative Learning in Rodents

(2014) Michael Bubser et al.   ACS Chemical Neuroscience

Antipsychotic Drug-Like Effects of the Selective M4 Muscarinic Acetylcholine Receptor Positive Allosteric Modulator VU0152100

(2014) Nellie E Byun et al.   NEUROPSYCHOPHARMACOLOGY

Effects of Selective Activation of M1 and M4 Muscarinic Receptors on Object Recognition Memory Performance in Rats

(2014) Claire R. Galloway et al.   PHARMACOLOGY

Improved cognition without adverse effects: novel M1 muscarinic potentiator compares favorably to donepezil and xanomeline in rhesus monkey

(2014) Joshua D. Vardigan et al.   PSYCHOPHARMACOLOGY

Effect of cholinergic neurotransmission modulation on visual spatial paired associate learning in healthy human adults

(2013) Brian T. Harel et al.   PSYCHOPHARMACOLOGY

Applicability of the CANTAB-PAL Computerized Memory Test in Identifying Amnestic Mild Cognitive Impairment and Alzheimer’s Disease

(2012) Jenny Junkkila et al.   DEMENTIA AND GERIATRIC COGNITIVE DISORDERS

The nicotinic α7 receptor agonist GTS-21 improves cognitive performance in ketamine impaired rhesus monkeys

(2012) Christopher E. Cannon et al.   NEUROPHARMACOLOGY

The novel phosphodiesterase 10A inhibitor THPP-1 has antipsychotic-like effects in rat and improves cognition in rat and rhesus monkey

(2012) Sean M. Smith et al.   NEUROPHARMACOLOGY

The muscarinic M1 receptor positive allosteric modulator PQCA improves cognitive measures in rat, cynomolgus macaque, and rhesus macaque

(2012) Jason M. Uslaner et al.   PSYCHOPHARMACOLOGY

M4 muscarinic receptor knockout mice display abnormal social behavior and decreased prepulse inhibition

(2012) Hisatsugu Koshimizu et al.   Molecular Brain

Muscarinic Acetylcholine Receptor Subtypes as Potential Drug Targets for the Treatment of Schizophrenia, Drug Abuse, and Parkinson’s Disease

(2011) Ditte Dencker et al.   ACS Chemical Neuroscience

Managing Cognitive Dysfunction through the Continuum of Alzheimerʼs Disease

(2011) Julien Delrieu et al.   CNS DRUGS

Muscarinic and Nicotinic Acetylcholine Receptor Agonists and Allosteric Modulators for the Treatment of Schizophrenia

(2011) Carrie K Jones et al.   NEUROPSYCHOPHARMACOLOGY

Modulation of prepulse inhibition through both M1 and M4 muscarinic receptors in mice

(2009) Morgane Thomsen et al.   PSYCHOPHARMACOLOGY

Selective Muscarinic Receptor Agonist Xanomeline as a Novel Treatment Approach for Schizophrenia

(2008) Anantha Shekhar et al.   AMERICAN JOURNAL OF PSYCHIATRY

Attenuation of amphetamine-induced activity by the non-selective muscarinic receptor agonist, xanomeline, is absent in muscarinic M4 receptor knockout mice and attenuated in muscarinic M1 receptor knockout mice

(2008) Marie L. Woolley et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Allosteric modulation of the muscarinic M4 receptor as an approach to treating schizophrenia

(2008) W. Y. Chan et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA